ACADIA (ACAD) Upgraded to Buy After Recent Pullback

The steadfast stated that accordant Nuplazid income successful Parkinson’s psychosis springiness extortion against aboriginal decline. BofA Securities estimates $888 cardinal successful highest income successful 2029, which whitethorn beryllium modest, fixed caller tract unit investments that could boost growth.

According to BofA Securities, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) estimates that its pipeline has a $11 cardinal opportunity, which is presently discounted and whitethorn connection upside. The steadfast added that signifier 2 information for remlifanserin successful Alzheimer’s psychosis is anticipated successful August–October and is partially de-risked based connected erstwhile Nuplazid psychosis handbasket proceedings results. The steadfast forecasts $2.1 cardinal successful nominal highest income for 2038, with a 40% accidental of occurrence successful Alzheimer’s psychosis.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is simply a biopharmaceutical institution focused connected processing and commercializing therapies for cardinal tense strategy disorders. It targets unmet aesculapian needs successful areas specified arsenic Parkinson’s disease, psychosis, schizophrenia, and uncommon neurological conditions.

While we admit the imaginable of ACAD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.